Volume 5, Issue 9: CFTR-Modifying Therapies
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 5, Issue 9)
Target Audience
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
Learning Objectives
After participating in this activity, the participant will demonstrate the ability to:
- Explain the relevance of specific mutations in people with CF to new therapies currently available or likely to be approved in the near future.
- Identify which patients are suitable for disease-modifying therapies based on mutation class.
- Explain the risk and benefits of CFTR modification therapy.
Stuart Elborn, MD
Professor, School of Medicine, Dentistry and Biomedical Sciences
Dean, School of Medicine, Dentistry and Biomedical Sciences
Centre for Infection and Immunity
Queen’s University
Belfast, Ireland
Available Credit
- 1.00 ANCC
- 1.00 Attendance